pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·Jul 23·1 min read
save

Nordic biotech must unite to become a global force, say venture investors

Jul 23, 2026·read at BioSpace ↗Neutral

The latest episode of BioSpace's podcast Denatured features Ester Sklarsky of Sound Bioventures and João Ribas of Novo Holdings Seed Investments discussing the future of Nordic biotech.

The guests note that the region, particularly Norway and Finland, remains fragmented and that a more coordinated approach will be needed for its companies to compete on a global scale.

They argue that aligning investment strategies and fostering cross-border collaboration could transform the Nordic ecosystem into a stronger international player.

source

This writeup was produced by pharmadog from original reporting by BioSpace.

Original headline: “Nordic biotech’s next act: From fragmentation to global force”

read at BioSpace ↗
284 words · retrieved Jul 23
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO5

related stories

  • May 7STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and moreSTAT
  • May 7STAT+: FDA revisits a rare cancer treatment it rejected a few months agoSTAT
  • May 7STAT+: FDA to reconsider treatment for rare cancer after its surprise rejectionSTAT
  • May 7STAT+: Next-gen Duchenne drug from Entrada disappointsSTAT
  • May 7STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1BSTAT